Related Experiment Videos
T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs
1Ben May Institute for Cancer Research, Department of Pathology, University of Chicago, IL 60637, USA.
Current Opinion in Immunology
|November 22, 1997
Abstract:
Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.